84 results about "CYP2D6 Gene" patented technology

The invention relates to a medicine metabolic relevant loci detection method, which comprises the following steps: extracting genome DNA from human samples; respectively designing a Taqman probe pair and a primer pair according to at least two medicine metabolic relevant genes; respectively marking the 5' end and the 3'end of the Taqman probe pair with fluorescence reporting genes and fluorescence quenching genes; carrying out fluorescence quantitative PCR augmentation on the genome DNA; and judging whether the medicine metabolic relevant genes have the mutation according to the fluorescence quantitative PCR augmentation results. Preferably, the number of the medicine metabolic relevant genes is four, the Taqman probe pair and the primer pair are used for detecting a loci rs1057910 of a gene CYP2C9, a loci rs4244285 of a gene CYP2C19, a loci rs4986893of a gene CYP2C19, a loci rs1065852 of a gene CYP2D6 and a loci rs28371759 of a gene CYP3A4. The invention has the advantages of ingenious design, simple operation and accurate and reliable detection results, and provides the reference frame for determining whether professional doctors are needed to be consulted so as to make sure the medicine can be taken or not or the proper dosage and the like when a certain medicine is taken.

The invention belongs to the field of biology and relates to a single base mutant at the 4094th site of CYP2D6 allele, wherein C at the site is mutated into A. The invention particularly relates to a nucleic acid segment containing the mutant site and a corresponding protein segment coded by the nucleic acid segment, a reagent and detection method for identifying the mutant site, application of the site, and especially application of identification of the site in medicine instruction.

The invention relates to a pyrosequencing primer pair for qualitatively detecting CYP2D6 genotyping; the primer pair includes a forward amplification primer and a reverse amplification primer, and a sequencing primer, and 5' ends of the forward amplification primer and reverse amplification primer are subjected to biotin labeling respectively; the invention also relates to a pyrosequencing kit for qualitatively detecting CYP2D6 genotyping; the kit includes amplification primers, PCR (polymerase chain reaction) liquid 1, PCR liquid 2, sequencing primers, uracil DNA glycosylase and Taq polymerase. The pyrosequencing primer pair and kit have the advantages that detection results are accurate, the specificity is high, detection period is short, operation is simple and clinical examination requirements can be effectively met and additionally have the advantages that reaction process can be monitored in real time, reaction time is short, PCR products can be fed to a pyrosequencing instrument for sequencing and high-throughput sample detection just through simple treatment, and the sensitivity is higher than that of a golden standard method, namely capillary electrophoresis sequencing method.

The invention belongs to the biological field, and relates to single base mutation of the 2519th locus of CYP2D6 allele. The locus is mutated into C from A. The invention concretely relates to a nucleic acid segment containing the mutation locus, a corresponding coded protein fragment, agents for identification of the mutation locus, a detection method and applications of the locus, especially applications of the identification of the locus in medication guidance.

The invention relates to a kit for detecting variation of the copy number of a CYP2D6 gene. The kit comprises a second intron, a sixth exon, a fifth intron and a reference gene RPP30 which are used for detecting the CYP2D6 gene, a real-time fluorescent quantitation technology is adopted, and the change of the copy number of the CYP2D6 gene is determined quickly and accurately; . By using the kit,high-throughput detection can be simultaneously conducted on three loci of the gene related to CYP2D6 under the same reaction condition, detection specificity is high, sensitivity is high, the minimumlowest detection limit is 1 ng / [mu]L, the consumed time is short, and the process from specimen inspection to result obtaining can be completed within two hours.

The invention provides a method for detecting copy number variation of a human CYP2D6 gene, the method comprises the following steps of: selecting two DNA sequences which have certain copy number and do not have copy number variation in a known genome of a sample to be detected as reference genes, calculating the difference Ct0 of Ct values of the two reference genes, and judging whether the degradation degree of the sample reaches the inaccurate detection degree or not; if the Ct0 reaches a threshold value which cannot ensure the accuracy of the detection result, prompting to re-sample for DNA extraction; and if the Ct0 is within a threshold range for ensuring the accuracy of the detection result, calculating the difference value between the Ct value of the CYP2D6 gene and the Ct value of one reference gene to obtain Ct1, and further judging the CYP2D6 copy number variation condition of the sample to be detected. According to the invention, the quality problem of the sample is eliminated, the accuracy of the CNV detection result is ensured, the operation is convenient and fast, the detection time is shortened, and the high cost caused by sequencing is saved.

The invention discloses a kit for detecting the curative effect of an individual antilipemic and antiatherosclerotic drug. The kit comprises a specific primer pair, a specific fluorescent probe pair, a fluorescence quantitative PCR conventional assembly and the like, and the specific primer pair is used for detecting a medication target site, namely a CYP3A4 gene, CYP2D6 gene and CYP2C9 gene polymorphism site of the statin drug. The kit can be used for estimating the curative effect of the individual antilipemic and antiatherosclerotic drug by detecting the medication target site, namely CYP3A4 gene, CYP2D6 gene and CYP2C9 gene polymorphism siteCYP3A4 gene, CYP2D6 gene and CYP2C9 gene polymorphism site of the statin drug.

The invention provides a CYP2D6 gene mutation detection liquid-phase chip which comprises ASPE (Allele Specific Primer Extension) primers aiming at CYP2D6 C2850T and CYP2D6Deletion mutational sites, three microballoons respectively enveloped with a specific anti-tag sequence and amplification primers aiming at the CYP2D6C2850T and the CYP2D6 Deletion mutational sites. The CYP2D6 gene mutation detection liquid-phase chip can simultaneously detect aiming at the CYP2D6 C2850T and the CYP2D Deletion mutational sites and has excellent signal to noise ratio. The coincidence ratio with a sequencing method of the CYP2D6 gene mutation detection liquid-phase chip reaches up to 100 percent, and the CYP2D6 gene mutation detection liquid-phase chip has higher specificity and precision compared with intra-class correlation products.

The invention discloses a gene polymorphism detection kit for guiding psychiatric medication. The kit comprises a specific primer group and a fluorescent probe group, wherein the specific primer group and the fluorescent probe group are used for detecting the rs1065852 site of a CYP2D6 gene, the rs1414334 site of an HTR2C gene, the rs1800497 site of an ANKK1 gene, the rs762551 site of a CYP1A2 gene, the rs489693 site of an MC4R gene and the rs1799978 site of a DRD2 gene. According to the invention, the primer group and the fluorescent probe group are utilized, and the template DNA is specifically amplified by using a fluorescent PCR amplification technology, so that the polymorphism of a plurality of sites of a plurality of genes related to psychotropic drugs can be accurately detected at the same time; ARMS primer design is adopted, mismatched bases are introduced, the specificity of primer amplification is improved, the sensitivity is high, and accurate genotyping can be conducted on human template DNA at the lowest DNA initial amount of 10 ng; the detection speed is high and the efficiency is high: the PCR reaction only needs less than 1 hour to complete the amplification reaction, the cost is lower, the required reagent consumables are all clinically common reagents, the cost is lower, and the clinical popularization is convenient.